AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma

Bispecific antibodies (bsAbs) are an emerging treatment modality particularly in hematologic malignancies such as the non-Hodgkin lymphomas follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Although bsAbs offer opportunities in the treatment of these conditions, they also present challenges, and additional longer-term data are needed to determine their optimal role. To discuss managed care approaches to bsAbs with a focus on FL and DLBCL, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in April 2025. Key insights from the discussion included that clinical efficacy is a primary consideration when evaluating the role of bsAbs in FL and DLBCL and that ongoing data collection is necessary for increased certainty in long-term outcomes, treatment comparisons, and real-world experience. Other insights related to treatment choice, site-of-care considerations, the evolving place of bsAbs in FL and DLBCL therapy, economic factors, and social determinants of health and equity. Suggested payer best practices for bsAbs in FL and DLBCL also emerged from the discussion.